Related Experiment Video

Updated: Aug 16, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Ad5CMVp53 gene therapy for locally advanced prostate cancer--where do we stand?

P Sweeney1, L L Pisters

  • 1Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

World Journal of Urology
|June 15, 2000
PubMed

Insights

This study evaluates p53 gene therapy (Ad5CMVp53) for locally advanced prostate cancer, offering a novel approach beyond traditional treatments. Researchers suggest using pathologic stage as an intermediate endpoint for faster treatment evaluation.

Area of Science:

  • Oncology
  • Molecular Oncology
  • Genetics

Background:

  • Locally advanced prostate cancer remains a challenge despite screening and awareness.
  • Traditional therapies like radiation and prostatectomy often fail to control local disease or impact disseminated cancer.
  • Novel molecular and genetic approaches are needed for improved treatment outcomes.

Purpose of the Study:

  • To evaluate the efficacy of p53 gene therapy (Ad5CMVp53) in patients with locally advanced prostate cancer.
  • To explore Ad5CMVp53 as a novel therapeutic strategy for prostate cancer.
  • To propose pathologic stage after therapy as an intermediate endpoint for rapid treatment evaluation.

Main Methods:

  • Clinical evaluation of Ad5CMVp53 (RPR/INGN 201) in a protocol for locally advanced prostate cancer.
  • Assessment of gene therapy's impact on prostate cancer progression.
  • Analysis of traditional versus proposed intermediate endpoints for treatment appraisal.

Main Results:

  • Ad5CMVp53 has shown prior promise in lung and head and neck cancers.
  • The study is currently evaluating this gene therapy in prostate cancer patients.
  • Traditional endpoints hinder rapid assessment and therapeutic strategy modification.

Conclusions:

  • p53 gene therapy represents a promising novel treatment for locally advanced prostate cancer.
  • Pathologic stage after therapy is suggested as a valuable intermediate endpoint for evaluating treatment efficacy.
  • Further research and clinical evaluation of gene therapy are warranted for prostate cancer management.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...